Amoéba: Emergency Authorization Granted for AXPERA Biocontrol Against Vine Downy Mildew
Amoéba announces the emergency market authorization for its biocontrol product AXPERA, valid for 120 days, to combat vine downy mildew in France. This new authorization, granted by the Ministry of Agriculture and Food Sovereignty, follows the one obtained in spring 2025.
The Ministry of Agriculture and Food Sovereignty has granted this emergency phytosanitary authorization for a period of 120 days, covering the anti-mildew product usage period from May to August 2026. This exceptional procedure allows French vineyard owners to immediately incorporate AXPERA into their mildew protection program, ahead of receiving permanent authorization. The final market authorization is expected in the coming weeks, currently in the last phase of evaluation by ANSES. This emergency request was advocated by the French Institute of Vine and Wine (IFV) and demonstrates the strong demand from vineyard professionals for the rapid use of AXPERA.
AXPERA: A Solution Amidst Mildew Challenges and Regulatory Restrictions
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Vine downy mildew causes significant yield losses and represents a phytosanitary emergency due to recent restrictions on copper usage, increasing resistance of mildew to conventional phytosanitary products, and heightened disease pressure exacerbated by climate change. In Bordeaux, the disease affected up to 90% of vineyards in 2024. AXPERA has proven effective against downy mildew in numerous tests conducted with technical prescribers and distributors. The solution can be used in programs and mixes, combined with a low dose of copper, accommodating the constraints related to limited authorized doses. Its multiple modes of action also allow vineyard owners to better manage the risk of resistances developed by mildew against conventional phytopharmaceutical solutions.
Sur la base de ses ressources actuelles, de son plan d'affaires et de la lettre de soutien de son actionnaire de référence, Amoéba estime pouvoir faire face à ses obligations jusqu'au 31 décembre 2026.
Risks mentioned
Autorisation définitive d'AXPERA obtenue tardivement (fin juin 2026) après période d'utilisation des produits, affectant les ventes du semestre
Monétisation de la plateforme cosmétique dont ni la réalisation, ni le calendrier, ni le montant ne sont acquis à ce jour
Besoin de levée de fonds supplémentaire pour assurer continuité d'exploitation jusqu'au 30 septembre 2027 et financer plan de développement
Opportunities identified
Autorisation pérenne AXPERA obtenue en France en juin 2026 ouvre la voie à la commercialisation en plusieurs pays européens
Accord majeur signé avec Syngenta pour distribution exclusive de la solution en céréales dans 27 pays UE, premiers lancements commerciaux attendus Q3 2028
Extension de l'accord de distribution Koppert jusqu'en juin 2031 et potentiel de monétisation de la plateforme cosmétique Willa™ dès 2027
Outlook / guidance
Expected revenue: 1,5 millions d'euros
Management commentary: Building on the outcomes of the various strategic initiatives undertaken since 2023, Amoéba will be able to leverage the ramp-up of its contracts in the agricultural sector from 2027 onwards to achieve revenue of between €1 million and €2 million.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
